Search Results

You are looking at 51 - 60 of 1,412 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Merkel Cell Carcinoma

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Dennis E. Hallahan, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Allan R. Oseroff, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, and Linda C. Wang

the express written permission of the NCCN © 2009. Disclosures for the NCCN Merkel Cell Carcinoma Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from

Full access

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

Background Adrenocortical carcinoma (ACC) is a rare but highly aggressive tumor with an estimated incidence of 0.7 to 2.0 per 1,000,000 adult individuals annually. 1 Radical surgery is still the mainstay treatment of patients with

Full access

Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma

Yue Chen, Zi-Qi Zheng, Fo-Ping Chen, Jian-Ye Yan, Xiao-Dan Huang, Feng Li, Ying Sun, and Guan-Qun Zhou

Background Adenoid cystic carcinoma (ACC) is a rare low-grade malignant tumor, accounting for approximately 1% of all head and neck malignancies. 1 ACC usually originates from many types of glands and most often arises in salivary glands

Full access

Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells

Robert J. Besaw, Adrienne R. Terra, Grace L. Malvar, Tobias R. Chapman, Lauren M. Hertan, and Benjamin L. Schlechter

Background Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC) of the pancreas is a rare pancreatic neoplasm, constituting an estimated 1.4% of pancreatic cancer diagnoses. 1 UCOGC is a clinically distinct variant of pancreatic

Full access

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia

As the incidence of ductal carcinoma in situ (DCIS) has increased, so has the number of DCIS survivors. 1 Most patients with DCIS are treated with breast-conserving surgery (BCS). 2 Radiation therapy (RT) and antiestrogen therapy (AET) have been

Full access

Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide

Kelly G. Paulson and Shailender Bhatia

Merkel Cell Carcinoma Presentation and Incidence Merkel cell carcinoma (MCC) typically presents as a rapidly enlarging red nodule on sun-exposed skin. 1 Risk factors include UV radiation exposure, age >65 years, and infection with the Merkel

Full access

Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

Background Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). Large institutional and population-based studies estimate the incidence of brain metastasis to be 5% to 20%, 1

Full access

Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options

Kelly N. Fitzgerald and Chung-Han Lee

Background Renal cell carcinoma (RCC) is the eighth most common malignancy in the United States; in 2020 alone, approximately 74,000 new cases of RCC were diagnosed and approximately 15,000 deaths were reported. 1 Historically, treatment

Full access

Surgical Management of Thyroid Carcinoma

Maria A. Kouvaraki, Suzanne E. Shapiro, Jeffrey E. Lee, Douglas B. Evans, and Nancy D. Perrier

therapy for papillary and follicular thyroid cancer . J Clin Endocrinol Metab 2001 ; 86 : 1447 – 1463 . 3 Hay ID Thompson GB Grant CS . Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in

Full access

Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA

Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, and Hai-Qiang Mai

Background Nasopharyngeal carcinoma (NPC), particularly the undifferentiated subtype, is prevalent in South Asia and South China. 1 , 2 Radiotherapy (RT) is the mainstay treatment of NPC. With the innovation of modern imaging and radiation